Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Down syndrome and Alzheimer's

Topic: Risk, prevention and care in population studies

Plain-language summary

Importance As the life expectancy of people with Down syndrome (DS) has markedly increased over the past decades, older adults with DS may be experiencing a higher incidence of aging conditions. In addition to longevity, the amyloid precursor protein gene located on chromosome 21 places individuals with DS at a high risk for developing Alzheimer disease. Yet, few studies have determined prevalence of dementia and comorbidities among older people with DS. Objective To determine the prevalence of dementia and aging-related comorbidities in older adult individuals with DS. Design, setting, and participants Cross-sectional analysis of 2015 California Medicare claims data. We examined 1 year of cross-sectional Medicare claims data that included 100% of Californian Medicare beneficiaries enrolled in both Medicare Part A and B in 2015. Of these 3 001 977 Californian Medicare beneficiaries 45 years or older, 878 individuals were identified as having a diagnosis of DS. Data were analyzed between April 2017 and February 2018. Main outcomes and measures The frequency of DS dementia was assessed across different age categories. The number and frequency of 27 comorbidities were compared among individuals with DS with and without dementia and by age and sex groups. Results A total of 353 DS individuals (40%) were identified as having dementia diagnoses (mean, 58.7 years; 173 women [49%]) and 525 without dementia diagnoses (mean, 55.9 years; 250 women [48%]). The frequency of DS dementia among those 65 years or older rose to 49%. The mean number of comorbidities per individual increased with age in general. Comorbid conditions were more numerous among those with dementia compared with those with DS without dementia (mean, 3.4 vs 2.5, respectively), especially among those younger than 65 years. In particular, 4 treatable conditions, hypothyroidism, epilepsy, anemia, and weight loss, were much more frequent in DS dementia. Conclusions and relevance Older Medicare beneficiaries in California with DS, especially those with dementia, have a high level of multimorbidity including several treatable conditions. While DS follow-up has long been confined to the pediatric sphere, we found that longevity in individuals with DS will necessitate complex adult and geriatric care. More evidenced-based and standardized follow-up could support better long-term comorbidity management and dementia care among aging adults with DS.

What this study adds

Evidence grade: Low

This is a cross-sectional study of 100 participants. In one year (2015) of California Medicare claims, 353 of 878 adults aged 45+ with Down syndrome (40%) had a dementia diagnosis, rising to 49% among those 65 or older. Those with dementia averaged more other health conditions (3.4 vs 2.5), and four treatable ones (hypothyroidism, epilepsy, anemia and weight loss) were much more frequent in them.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bayen, E., Possin, K. L., Chen, Y., Cleret de Langavant, L., & Yaffe, K. (2018). Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome. JAMA neurology. https://doi.org/10.1001/jamaneurol.2018.2210

Vancouver

Bayen E, Possin KL, Chen Y, Cleret de Langavant L, Yaffe K. Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome. JAMA neurology. 2018. doi:10.1001/jamaneurol.2018.2210. PMID: 30032260.

BibTeX

@article{bayen2018-30032260,
  author  = {Bayen, E. and Possin, K. L. and Chen, Y. and Cleret de Langavant, L. and Yaffe, K.},
  title   = {{Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome}},
  journal = {JAMA neurology},
  year    = {2018},
  doi     = {10.1001/jamaneurol.2018.2210},
  pmid    = {30032260},
  url     = {https://doi.org/10.1001/jamaneurol.2018.2210}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In one year (2015) of California Medicare claims, 353 of 878 adults aged 45+ with Down syndrome (40%) had a dementia diagnosis, rising to 49% among those 65 or older. Those with dementia averaged more other health conditions (3.4 vs 2.5), and four treatable ones (hypothyroidism, epilepsy, anemia and weight loss) were much more frequent in them. The authors conclude that adults with Down syndrome need "complex adult and geriatric care". The study only counts diagnoses at one point in time; it does not show what causes what or test any treatment.

Study details

How this study scored 61/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 4 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 61 of 100.61 of 100 points earned39 not earned

Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record 2 / 4 JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 2 / 4 100 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 125 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 12.5 citations a year over 10 year(s) since 2018
Impact for its field and year 4 / 6 Cited 10.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 11 other studies in this library
Still being cited 2 / 4 Cited 41 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Kristine S. Yaffe: h-index 155 (OpenAlex, whole career)
Institution's track record 2 / 3 Inserm: institution h-index 1,988 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 11 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 30032260)
Free to read 0 / 2 Behind a paywall — scores zero
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Down syndrome and Alzheimer's from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →